Xeris Biopharma Holdings, Inc. (XERS)

Xeris Biopharma Holdings, Inc. is trading at $8.71, up 2.23% on the session. The 50 day average sits at $7.75 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 58.6, which reads as strong, and MACD is bearish crossover. Volume is below average.

The nearest support is around $8.00 with resistance near $9.00, so that band frames the current range. Average daily movement is roughly $0.39, or about 4.4% of the share price, which is what any stop placement has to allow for. The overall health score of 64 out of 100 combines a trend score of 75, momentum of 55 and a risk score of 58.

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.